BioNexus Gene Lab Corp.
BGLC · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $9,511 | $9,771 | $10,929 | $13,363 |
| % Growth | -2.7% | -10.6% | -18.2% | – |
| Cost of Goods Sold | $8,221 | $8,441 | $9,670 | $11,169 |
| Gross Profit | $1,290 | $1,329 | $1,259 | $2,194 |
| % Margin | 13.6% | 13.6% | 11.5% | 16.4% |
| R&D Expenses | $48 | $55 | $0 | $0 |
| G&A Expenses | $1,974 | $2,443 | $1,729 | $1,204 |
| SG&A Expenses | $4,005 | $3,040 | $1,729 | $1,204 |
| Sales & Mktg Exp. | $2,031 | $597 | $0 | $0 |
| Other Operating Expenses | -$1,189 | $828 | -$179 | -$66 |
| Operating Expenses | $2,863 | $3,923 | $1,550 | $1,138 |
| Operating Income | -$1,574 | -$2,594 | -$291 | $1,056 |
| % Margin | -16.5% | -26.5% | -2.7% | 7.9% |
| Other Income/Exp. Net | -$21 | -$14 | -$12 | -$13 |
| Pre-Tax Income | -$1,595 | -$2,608 | -$304 | $1,043 |
| Tax Expense | $3 | $22 | $52 | $291 |
| Net Income | -$1,598 | -$2,629 | -$356 | $752 |
| % Margin | -16.8% | -26.9% | -3.3% | 5.6% |
| EPS | -0.9 | -1.53 | -0.25 | 0.53 |
| % Growth | 41.2% | -512% | -147.2% | – |
| EPS Diluted | -0.9 | -1.53 | -0.25 | 0.53 |
| Weighted Avg Shares Out | 1,782 | 1,722 | 1,441 | 1,427 |
| Weighted Avg Shares Out Dil | 1,782 | 1,722 | 1,441 | 1,427 |
| Supplemental Information | – | – | – | – |
| Interest Income | $148 | $0 | $0 | $0 |
| Interest Expense | $21 | $14 | $12 | $13 |
| Depreciation & Amortization | $153 | $108 | $105 | $108 |
| EBITDA | -$1,421 | -$2,485 | -$186 | $1,164 |
| % Margin | -14.9% | -25.4% | -1.7% | 8.7% |